Research programme: bispecific antibodies - Xencor
Alternative Names: PSMA x CD3 bispecific antibodies - Xencor; XmAb 2+1 PSMA x CD3 bispecific antibodies - XencorLatest Information Update: 28 Jun 2024
At a glance
- Originator Xencor
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Prostate-cancer in USA (Parenteral)